Flmodafinil
chemical compound
Flmodafinil (developmental code names CRL-40,940, NLS-4, JBG01-41), also known as bisfluoromodafinil and lauflumide, is a wakefulness-promoting agent related to modafinil which has been developed for treatment of a variety of different medical conditions. These include chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease. Aside from its development as a potential pharmaceutical drug, flmodafinil is sold online and used non-medically as a nootropic (cognitive enhancer).
The drug has been found to act as a selective atypical dopamine reuptake inhibitor. It produces wakefulness-promoting effects in animals. Unlike modafinil, flmodafinil does not induce cytochrome P450 enzymes. Chemically, flmodafinil is an enantiopure derivative of modafinil and is also known as bisfluoromodafinil (it is the (R)-bis(4-fluoro) phenyl ring-substituted derivative of modafinil).
Flmodafinil was developed by NLS Pharma. As of January 2024, it is in preclinical development for treatment of chronic fatigue syndrome. No recent development has been reported for idiopathic hypersomnia and development has been discontinued for narcolepsy, ADHD, and Alzheimer's disease.
“Flmodafinil” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Flmodafinil, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Flmodafinil” is worth following because a concise public description often conceals a longer documentary argument. Here, Flmodafinil, chemical and compound provides the most credible route into that argument.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 10, 2026. The linked authority identifier is Q21098952. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Flmodafinil”, its source revision and the description used here.
- Expand the search: follow Flmodafinil primary sources, Flmodafinil archive and Flmodafinil research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Flmodafinil”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Flmodafinil” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.